NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis $7.85 -0.05 (-0.63%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.71▼$8.0750-Day Range N/A52-Week Range$4.00▼$10.24Volume430,138 shsAverage Volume300,024 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipShort InterestTrends Get Actinium Pharmaceuticals alerts: Email Address Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Actinium PharmaceuticalsActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.Read More ATNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNM Stock News HeadlinesJuly 25 at 8:31 PM | tmcnet.comCCPayment Unveils Swap API: Pioneering the Next Era of Cryptocurrency TransactionsJuly 25 at 1:29 PM | msn.comActinium wins FDA nod to conduct clinical trial for radiotherapyJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 25 at 8:45 AM | prnewswire.comActinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia UniversityJuly 25 at 8:27 AM | forbes.comDon't Leave The Door Open: The API Model To Defend Against IntrudersJuly 25 at 7:30 AM | prnewswire.comActinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit USJuly 23, 2024 | msn.comBridge Alliance and Singtel partner to launch regional telco API exchange powered by Singtel Paragon platformJuly 23, 2024 | money.usnews.comActinium Pharmaceuticals IncJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 22, 2024 | msn.comAPI Consumption Under the Microscope: Key Takeaways from Lunar.dev's Comprehensive ReportJuly 22, 2024 | msn.comEconomic Survey 2024: India's pharma exports surge to $27.9 billion, API imports pose challengeJuly 22, 2024 | businesswire.comNorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 ProductionJuly 19, 2024 | msn.comGoogle slashes maps API prices in India – weeks after a competitor emergedJuly 11, 2024 | investorplace.com3 Under-$10 Biotech Stocks That Could Make You RichJuly 2, 2024 | investorplace.com3 Clinical-Stage Biotech Stocks to Buy for Multibagger ReturnsJune 17, 2024 | prnewswire.comActinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA CongressJune 14, 2024 | prnewswire.comActinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA TrialJune 11, 2024 | prnewswire.comActinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today7/26/2024Next Earnings7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ATNM CUSIPN/A CIKN/A WebN/A Phone(646) 677-3870FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key CompetitorsAesther Healthcare AcquisitionNASDAQ:AEHAWAlvotechNASDAQ:ALVOWAmpio PharmaceuticalsNYSE:AMPEAtlantic Coastal Acquisition Corp. IINASDAQ:ACABWBioLingus (Cayman)NASDAQ:SUBLView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 19,035 shares on 7/26/2024Ownership: 0.290%Virtu Financial LLCBought 62,459 shares on 5/20/2024Ownership: 0.275%Vanguard Group Inc.Bought 82,113 shares on 5/10/2024Ownership: 4.857%View All Institutional Transactions ATNM Stock Analysis - Frequently Asked Questions How have ATNM shares performed this year? Actinium Pharmaceuticals' stock was trading at $5.24 at the start of the year. Since then, ATNM shares have increased by 49.8% and is now trading at $7.85. View the best growth stocks for 2024 here. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.01. When did Actinium Pharmaceuticals' stock split? Actinium Pharmaceuticals shares reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Actinium Pharmaceuticals' major shareholders? Top institutional investors of Actinium Pharmaceuticals include Bank of New York Mellon Corp (0.29%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT) and Abiomed (ABMD). This page (NYSE:ATNM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
